StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)

Close on Nov 17, 2026Market cap $792.02MP/E –Yield –

Lexicon Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Lexicon Pharmaceuticals's total assets was $250.06M at Jun 30, 2026. For fiscal 2025 it was $184.99M, down 38.0% from the year before. Over ten years it grew -11.8% a year on average. The highest annual figure on record is $651.96M in fiscal 2015.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$184.99M-38.0%
FY2024Dec 31, 2024$298.42M+30.1%
FY2023Dec 31, 2023$229.43M+18.1%
FY2022Dec 31, 2022$194.30M+41.9%
FY2021Dec 31, 2021$136.91M-32.8%
FY2020Dec 31, 2020$203.79M-51.2%
FY2019Dec 31, 2019$417.72M+47.0%
FY2018Dec 31, 2018$284.14M-34.9%
FY2017Dec 31, 2017$436.54M-8.2%
FY2016Dec 31, 2016$475.63M-27.0%
FY2015Dec 31, 2015$651.96M+38.3%
FY2014Dec 31, 2014$471.38M+71.9%
FY2013Dec 31, 2013$274.16M-26.3%
FY2012Dec 31, 2012$371.78M-13.6%
FY2011Dec 31, 2011$430.51M+17.3%
FY2010Dec 31, 2010$366.88M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$250.06M+10.9%
Q1 FY2026Mar 31, 2026$268.82M-9.7%
Q4 FY2025Dec 31, 2025$184.99M-38.0%
Q3 FY2025Sep 30, 2025$205.93M-35.9%
Q2 FY2025Jun 30, 2025$225.58M-39.6%
Q1 FY2025Mar 31, 2025$297.67M-28.7%
Q4 FY2024Dec 31, 2024$298.42M+30.1%
Q3 FY2024Sep 30, 2024$321.12M+16.1%
Q2 FY2024Jun 30, 2024$373.36M+17.9%
Q1 FY2024Mar 31, 2024$417.22M+156.4%
Q4 FY2023Dec 31, 2023$229.43M+18.1%
Q3 FY2023Sep 30, 2023$276.48M+44.2%
Q2 FY2023Jun 30, 2023$316.72M+182.0%
Q1 FY2023Mar 31, 2023$162.72M+19.5%
Q4 FY2022Dec 31, 2022$194.30M+41.9%
Q3 FY2022Sep 30, 2022$191.69M+11.2%
Q2 FY2022Jun 30, 2022$112.33M-34.6%
Q1 FY2022Mar 31, 2022$136.18M-29.5%
Q4 FY2021Dec 31, 2021$136.91M-32.8%
Q3 FY2021Sep 30, 2021$172.33M-3.7%
Q2 FY2021Jun 30, 2021$171.67M-46.8%
Q1 FY2021Mar 31, 2021$193.26M-47.8%
Q4 FY2020Dec 31, 2020$203.79M-51.2%
Q3 FY2020Sep 30, 2020$178.93M-59.8%
Q2 FY2020Jun 30, 2020$322.54M+38.3%
Q1 FY2020Mar 31, 2020$370.57M+43.3%
Q4 FY2019Dec 31, 2019$417.72M+47.0%
Q3 FY2019Sep 30, 2019$444.59M+43.3%
Q2 FY2019Jun 30, 2019$233.14M-30.0%
Q1 FY2019Mar 31, 2019$258.52M-33.2%
Q4 FY2018Dec 31, 2018$284.14M-34.9%
Q3 FY2018Sep 30, 2018$310.19M-5.9%
Q2 FY2018Jun 30, 2018$332.94M-8.4%
Q1 FY2018Mar 31, 2018$386.81M-2.4%
Q4 FY2017Dec 31, 2017$436.54M-8.2%
Q3 FY2017Sep 30, 2017$329.49M-36.3%
Q2 FY2017Jun 30, 2017$363.51M–
Q1 FY2017Mar 31, 2017$396.26M–
Q4 FY2016Dec 31, 2016$475.63M–
Q3 FY2016Sep 30, 2016$516.95M–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?